Unknown

Dataset Information

Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.


ABSTRACT:

Background

Genome editing offers unique perspectives for optimizing the functional properties of T cells for adoptive cell transfer purposes. So far, PDCD1 editing has been successfully tested mainly in chimeric antigen receptor T (CAR-T) cells and human primary T cells. Nonetheless, for patients with solid tumors, the adoptive transfer of effector memory T cells specific for tumor antigens remains a relevant option, and the use of high avidity T cells deficient for programmed cell death-1 (PD-1) expression is susceptible to improve the therapeutic benefit of these treatments.

Methods

Here we used the transfection of CAS9/sgRNA ribonucleoproteic complexes to edit PDCD1 gene in human effector memory CD8+ T cells specific for the melanoma antigen Melan

SUBMITTER: Marotte L 

PROVIDER: S-EPMC7057432 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature